SEC Form 4 · accession 0001193125-26-259705
CG Oncology, Inc. · CGON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard E Post
Director
Period of report
Jun 4, 2026
Accepted (ET)
Jun 5, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001991792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 4, 2026 | M | 1,000 | $0.60 | A | 1,000 | D | |
| Common Stock | Jun 4, 2026 | S | 1,000 | $54.50 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $0.60 | Jun 4, 2026 | M | 1,000 | D | — | Jul 8, 2028 | Common Stock | 1,000 | 116,077 | D |
| Director Stock Option (right to buy)F3 | $56.09 | Jun 4, 2026 | A | 9,354 | A | — | Jun 3, 2036 | Common Stock | 9,354 | 9,354 | D |
Explanation of responses
- F1The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026
- F2Fully vested.
- F31/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.